Aurora Cannabis Ships Products to Maltese Medical Cannabis Market

Aurora Cannabis Inc. (TSX: ACB) (OTCQB: ACBFF) (Frankfurt: 21P; WKN: A1C4WM) today announced that the Company, through its wholly owned German subsidiary Pedanios GmbH, has become the first licensed provider of medical cannabis to patients in Malta. The import permit issued by the Malta Medicines Authority was obtained on June 5, 2018, and Pedanios obtained the required export permit from German authorities on June 21, 2018. Following Italy and Germany, Malta is the third European Union member country where medical cannabis is currently sold by Pedanios.

Two goods, Pedanios 22/1 and 20/1, are being shipped to Malta today, and will become available in Maltese pharmacies shortly. Pedanios expects pharmacists will have the ability to fill patient prescriptions within approximately two weeks. These orders include approved vaporization devices for patients’ consumption of Aurora cannabis products.

Market entrance in Malta was achieved through close cooperation with Aurora’s local distribution partner Cherubino Ltd. (“Cherubino”), the largest pharmaceutical wholesaler in Malta, who have over 100 years of operating history. This partnership was instrumental in navigating the rigorous legislative requirements of the MMA to supply high-quality medical cannabis to Maltese patients. The Maltese parliament on March 26, 2018 legalized medical cannabis.

“We are extremely happy that through Pedanios, Aurora is the first provider of medical cannabis to Maltese patients,” stated Neil Belot, Chief Global Business Development Officer. “With an established and highly regarded team, as well as unique regional distribution relationships, Pedanios provides Aurora with an early mover advantage in the big, highly regulated European market. Providing products to the medical cannabis system further strengthens our visibility and brand recognition in Europe and internationally.”

Mario Reichenbach, Head of Business Development in Pedanios added,”Pedanios is focused on enhancing patient welfare through the delivery of high-quality medical products, and we are very proud to now extend our reach to the citizens of Malta. This is a significant milestone for Maltese patients that have been waiting for medical cannabis to become available in their country. Our achievement was driven by the professionalism of our neighborhood partner, Cherubino, the dedication of the government to implement a legislative framework to support its citizens, and the hard work of our European team. Our relationship with Cherubino will continue to grow, as we intend to provide ongoing support for education of Maltese doctors about the benefits, risks and side effects which may apply with respect to the use of medical cannabis in the management of symptoms associated with a variety of chronic health conditions.”

Headquartered in Edmonton, Alberta, with funded capacity in excess of 430,000 kg annually and operations across Canada and in Europe, Aurora is one of the world’s biggest cannabis companies. The Company is vertically integrated and horizontally diversified across every key sector of the value chain, from facility design and technology, to cannabis breeding and genetics research, cannabis and hemp production, extraction and high value-add product development, home cultivation and wholesale and retail distribution.

Highly distinguished from its peers, Aurora has established a uniquely advanced, consistent and effective production strategy, based on purpose-built facilities which incorporate leading-edge technologies across all processes. Intended to be replicable and scalable worldwide, these production facilities are intended to make cannabis on a gigantic scale, with high flower quality, industry-leading yields, and ultra-low per g production costs. Each of the business’s facilities is built to meet European Union (EU) GMP standards, and its first production facility and its wholly owned European medical cannabis distributor Pedanios have achieved that level of certification.

For more information about Aurora, please see our investor website investor.auroramj.com.

SOURCE

Published at Mon, 25 Jun 2018 14:29:03 +0000

Posted in: News

Comments are closed.